Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke|
|Citation:||Brain Research, 2011; 1393:84-90|
|Publisher:||Elsevier Science Bv|
|Renée J. Turner, Stephen C. Helps, Emma Thornton and Robert Vink|
|Abstract:||Previous studies have suggested that substance P (SP) plays a critical role in the development of brain oedema and functional deficits following traumatic brain injury and that SP receptor antagonism may improve outcome. No studies have described such a role in ischemic stroke. The present study characterized the effects of the NK1 tachykinin receptor antagonist, n-acetyl-L-tryptophan (NAT), on blood-brain barrier (BBB) breakdown, oedema formation, infarct volume and functional outcome following reversible ischemic stroke in rats. Ischemia was induced using a reversible thread model of middle cerebral artery occlusion where occlusion was maintained for 2 h before reperfusion. Animals received either NAT or equal volume saline vehicle intravenously at 2 h post-reperfusion. Ischaemic stroke resulted in increased perivascular SP immunoreactivity at 24 h. Administration of NAT significantly reduced oedema formation and BBB permeability at 24 h post-ischemia and significantly improved functional outcome as assessed over 7 days. There was no effect on infarct volume. We conclude that inhibition of SP activity with a NK1 tachykinin receptor antagonist is effective in reducing cerebral oedema, BBB permeability and functional deficits following reversible ischemia and may therefore represent a novel therapeutic approach to the treatment of ischaemic stroke.|
|Keywords:||Ischaemic stroke; NK1 tachykinin receptor antagonist; Oedema; Neuropeptides; Neurogenic inflammation|
|Rights:||© 2011 Elsevier B.V. All rights reserved.|
|Appears in Collections:||Medical Sciences publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.